Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636820 | 0.84 | CRHR1 (0.67) | CRHR1TDP1MAP2K7 | |
| SCHEMBL1637024 | 0.83 | CRHR1 (0.60) | CRHR1TDP1KDM4EALOX15CASP1 | |
| SCHEMBL12534721 | 0.83 | CRHR1 (0.60) | CRHR1TDP1MAP2K7 | |
| SCHEMBL1636150 | 0.81 | CRHR1 (0.64) | CRHR1TDP1KDM4EALOX15CASP1 | |
| SCHEMBL12534771 | 0.81 | CRHR1 (0.64) | CRHR1TDP1MAP2K7 | |
| SCHEMBL1636997 | 0.80 | CRHR1 (0.62) | CRHR1TDP1MAP2K7 | |
| SCHEMBL14536212 | 0.79 | CRHR1 (0.60) | CRHR1TDP1 | |
| SCHEMBL12593279 | 0.78 | CRHR1 (0.60) | CRHR1TDP1KDM4EHSD17B10MAPT | |
| SCHEMBL1636376 | 0.77 | CRHR1 (0.53) | CRHR1TDP1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL1637910 | 0.77 | CRHR1 (0.53) | CRHR1TDP1NPY5RMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885TDP1 4399/4885KDM4E 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.